"Belzutifan Shows Promising Efficacy in Rare Neuroendocrine Tumors"

A Phase II clinical trial at The University of Texas MD Anderson Cancer Center revealed that Belzutifan effectively shrinks tumors in advanced pheochromocytoma and paraganglioma, marking a potential breakthrough in treating neuroendocrine tumors.

• The study, led by Camilo Jimenez, M.D., showed promising results for the enzyme inhibitor Belzutifan in controlling advanced paraganglioma and pheochromocytoma, both rare neuroendocrine tumors.
• Significant tumor shrinkage was observed in patients with these neoplasms, providing hope for better treatment options in a field where metastasis often complicates outcomes.
• Published findings from the trial will be presented at the upcoming European Society for Medical Oncology meeting, highlighting advancements in the phases of clinical research for cancer therapies.